Kyprolis Side Effects Center

Last updated on RxList: 9/16/2022
Kyprolis Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Kyprolis?

Kyprolis (carfilzomib) is an antineoplastic agent indicated to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory therapy.

What Are Side Effects of Kyprolis?

Common side effects of Kyprolis are:

Serious side effects of Kyprolis include:

Patients should be monitored closely and treatment withheld if these serious side effects of Kyprolis occur.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheartedness, or passing out;
  • Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Kyprolis

Kyprolis is administered intravenously over 2 to 10 minutes, on two consecutive days each week for three weeks, followed by a 12-day rest period. The recommended cycle 1 dose is 20 mg/m2/day and if tolerated increase cycle 2 dose and subsequent cycles doses to 27 mg/m2/day.

What Drugs, Substances, or Supplements Interact with Kyprolis?

Other drugs may interact with Kyprolis. Tell your doctor all medications you use. Kyprolis can cause fetal harm. Women should avoid becoming pregnant while being treated.

Kyprolis During Pregnancy and Breastfeeding

Female patients should be advised that if she becomes pregnant during treatment, to contact her physician immediately. Advise patients not to take Kyprolis treatment while pregnant or breastfeeding. If a patient wishes to restart breastfeeding after treatment, advise her to discuss the appropriate timing with her physician.

Additional Information

Our Kyprolis Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow
Kyprolis Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur within 24 hours after the injection. Tell your caregiver right away if you feel weak, nauseated, chilled or feverish, light-headed, or if you have joint or muscle pain, a cold sweat, chest pain or tightness, trouble breathing, or swelling in your face.

Carfilzomib may cause a serious brain infection that can lead to disability or death. Call your doctor right away if you have problems with speech, thought, vision, or muscle movement. These symptoms may start gradually and get worse quickly.

Also call your doctor at once if you have:

  • a light-headed feeling, like you might pass out;
  • easy bruising or bleeding (nosebleeds, bleeding gums), or any bleeding that will not stop;
  • vomiting, diarrhea, weakness, blood in your stools, coughing up blood or vomit that looks like coffee grounds;
  • headache, confusion, dizziness, problems with balance;
  • a seizure;
  • jaundice (yellowing of the skin or eyes);
  • heart problems--chest pain, pain spreading to your jaw or shoulder, pounding in your neck or ears, blurred vision, severe headache;
  • kidney problems--little or no urination, swelling in your feet or ankles, feeling tired or short of breath;
  • low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, pale skin, cold hands and feet;
  • lung problems--shortness of breath (even while lying down), wheezing, blue colored lips and skin, cough with foamy mucus;
  • low potassium level--leg cramps, irregular heartbeats, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling;
  • signs of a blood clot--sudden numbness or weakness, slurred speech, pain or redness in an arm or leg; or
  • signs of tumor cell breakdown--weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet or around your mouth.

Common side effects may include:

  • fever, bruising, pale skin or other signs of low blood cell counts;
  • feeling short of breath;
  • low potassium;
  • nausea, diarrhea;
  • cold symptoms such as stuffy nose, sneezing, cough, sore throat;
  • muscle spasm;
  • swelling in your hands or feet; or
  • headache, trouble sleeping, feeling tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Kyprolis Professional Information

SIDE EFFECTS

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Cardiac Toxicities [see WARNINGS AND PRECAUTIONS]
  • Acute Renal Failure [see WARNINGS AND PRECAUTIONS]
  • Tumor Lysis Syndrome [see WARNINGS AND PRECAUTIONS]
  • Pulmonary Toxicity [see WARNINGS AND PRECAUTIONS]
  • Pulmonary Hypertension [see WARNINGS AND PRECAUTIONS]
  • Dyspnea [see WARNINGS AND PRECAUTIONS]
  • Hypertension [see WARNINGS AND PRECAUTIONS]
  • Venous Thrombosis [see WARNINGS AND PRECAUTIONS]
  • Infusion-Related Reactions [see WARNINGS AND PRECAUTIONS]
  • Hemorrhage [see WARNINGS AND PRECAUTIONS]
  • Thrombocytopenia [see WARNINGS AND PRECAUTIONS]
  • Hepatic Toxicity and Hepatic Failure [see WARNINGS AND PRECAUTIONS]
  • Thrombotic Microangiopathy [see WARNINGS AND PRECAUTIONS]
  • Posterior Reversible Encephalopathy Syndrome [see WARNINGS AND PRECAUTIONS]
  • Progressive Multifocal Leukoencephalopathy [see WARNINGS AND PRECAUTIONS]

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The pooled safety population described in the Warnings and Precautions reflect exposure to Kyprolis in 2,239 patients administered in combination with other drugs in ASPIRE, ENDEAVOR, A.R.R.O.W., CANDOR, IKEMA, EQUULEUS, and PLEIADES. The most common adverse reactions occurring in at least 20% of patients who received Kyprolis in combination were anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, and insomnia.

Kyprolis In Combination With Lenalidomide And Dexamethasone

The safety of Kyprolis 20/27 mg/m2 twice weekly in combination with lenalidomide and dexamethasone (KRd) was evaluated in ASPIRE [see Clinical Studies]. The median number of cycles initiated was 22 cycles for the KRd arm and 14 cycles for the Rd arm.

Deaths due to adverse reactions within 30 days of the last dose of any therapy in the KRd arm occurred in 45/392 (12%) patients compared with 42/389 (11%) patients who died due to adverse reactions within 30 days of the last dose of any Rd therapy. The most frequent cause of deaths occurring in patients (%) in the two arms (KRd versus Rd) included infection 12 (3%) versus 11 (3%), cardiac 10 (3%) versus 9 (2%), and other adverse reactions 23 (6%) versus 22 (6%).

Serious adverse reactions were reported in 65% of the patients in the KRd arm and 57% of the patients in the Rd arm. The most frequent serious adverse reactions reported in the KRd arm as compared with the Rd arm were pneumonia (17% versus 13%), respiratory tract infection (4% versus 2%), pyrexia (4% versus 3%), and pulmonary embolism (3% versus 2%).

Discontinuation due to any adverse reaction occurred in 33% in the KRd arm versus 30% in the Rd arm. Adverse reactions leading to discontinuation of Kyprolis occurred in 12% of patients and the most common reactions included pneumonia (1%), myocardial infarction (0.8%), and upper respiratory tract infection (0.8%). The incidence of cardiac failure events was 7% in the KRd arm versus 4% in the Rd arm.

Table 8 summarizes the adverse reactions in the first 12 cycles in ASPIRE.

Table 8: Adverse Reactions (≥ 10%) Occurring in Cycles 1–12 in Patients Who Received KRd (20/27 mg/m2 Regimen) in ASPIRE

Adverse Reactions KRd
(N = 392)
n (%)
Rd
(N = 389)
n (%)
Any Grade ≥ Grade 3 Any Grade ≥ Grade 3
Blood and Lymphatic System Disorders
  Anemia 138 (35) 53 (14) 127 (33) 47 (12)
  Neutropenia 124 (32) 104 (27) 115 (30) 89 (23)
  Thrombocytopenia 100 (26) 58 (15) 75 (19) 39 (10)
Gastrointestinal Disorders
  Diarrhea 119 (30) 8 (2) 106 (27) 12 (3)
  Constipation 68 (17) 0 (0) 55 (14) 1 (0)
  Nausea 63 (16) 1 (0) 43 (11) 3 (1)
General Disorders and Administration Site Conditions
  Fatigue 113 (29) 23 (6) 107 (28) 20 (5)
  Pyrexia 93 (24) 5 (1) 64 (17) 1 (0)
  Edema peripheral 59 (15) 3 (1) 48 (12) 2 (1)
  Asthenia 54 (14) 11 (3) 49 (13) 7 (2)
Infections
  Upper respiratory tract infection 87 (22) 7 (2) 54 (14) 4 (1)
  Bronchitis 55 (14) 5 (1) 40 (10) 2 (1)
  Viral upper respiratory tract infection 55 (14) 0 (0) 44 (11) 0 (0)
  Pneumoniaa 54 (14) 35 (9) 43 (11) 27 (7)
Metabolism and Nutrition Disorders
  Hypokalemia 78 (20) 22 (6) 35 (9) 12 (3)
  Hypocalcemia 55 (14) 10 (3) 39 (10) 5 (1)
  Hyperglycemia 43 (11) 18 (5) 33 (9) 15 (4)
Musculoskeletal and Connective Tissue Disorders
  Muscle spasms 92 (24) 3 (1) 75 (19) 3 (1)
  Back pain 41 (11) 4 (1) 54 (14) 6 (2)
Nervous System Disorders
  Peripheral neuropathiesb 43 (11) 7 (2) 39 (10) 4 (1)
Psychiatric Disorders
  Insomnia 64 (16) 6 (2) 51 (13) 8 (2)
Respiratory, Thoracic and Mediastinal Disorders
  Coughc 93 (24) 2 (1) 54 (14) 0 (0)
  Dyspnead 71 (18) 8 (2) 61 (16) 6 (2)
Skin and Subcutaneous Tissue Disorders
  Rash 45 (12) 5 (1) 54 (14) 5 (1)
Vascular Disorders
  Embolic and thrombotic eventse 49 (13) 16 (4) 23 (6) 9 (2)
  Hypertensionf 41 (11) 12 (3) 15 (4) 4 (1)
KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone
a Pneumonia includes pneumonia and bronchopneumonia.
b Peripheral neuropathies includes peripheral neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy.
c Cough includes cough and productive cough.
d Dyspnea includes dyspnea and dyspnea exertional.
e Embolic and thrombotic events, venous includes deep vein thrombosis, pulmonary embolism, thrombophlebitis superficial, thrombophlebitis, venous thrombosis limb, post thrombotic syndrome, venous thrombosis.
f Hypertension includes hypertension, hypertensive crisis.

There were 274 (70%) patients in the KRd arm who received treatment beyond Cycle 12. There were no new clinically relevant adverse reactions that emerged in the later treatment cycles.

Adverse Reactions Occurring At A Frequency Of < 10%

  • Blood and lymphatic system disorders: febrile neutropenia, lymphopenia
  • Cardiac disorders: cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, pericardial effusion
  • Ear and labyrinth disorders: deafness, tinnitus
  • Eye disorders: cataract, vision blurred
  • Gastrointestinal disorders: abdominal pain, abdominal pain upper, dyspepsia, gastrointestinal hemorrhage, toothache
  • General disorders and administration site conditions: chills, infusion site reaction, multi-organ failure, pain
  • Infections: clostridium difficile colitis, influenza, lung infection, rhinitis, sepsis, urinary tract infection, viral infection
  • Metabolism and nutrition disorders: dehydration, hyperkalemia, hyperuricemia, hypoalbuminemia, hyponatremia, tumor lysis syndrome
  • Musculoskeletal and connective tissue disorders: muscular weakness, myalgia
  • Nervous system disorders: hypoesthesia, intracranial hemorrhage, paresthesia
  • Psychiatric disorders: anxiety, delirium
  • Renal and urinary disorders: renal failure, renal failure acute, renal impairment
  • Respiratory, thoracic and mediastinal disorders: dysphonia, epistaxis, oropharyngeal pain, pulmonary embolism, pulmonary edema, pulmonary hemorrhage
  • Skin and subcutaneous tissue disorders: erythema, hyperhidrosis, pruritus
  • Vascular disorders: deep vein thrombosis, hemorrhage, hypotension

Grade 3 and higher adverse reactions that occurred during Cycles 1–12 with a substantial difference (≥ 2%) between the two arms were neutropenia, thrombocytopenia, hypokalemia, and hypophosphatemia.

Table 9 describes Grade 3–4 laboratory abnormalities reported in ASPIRE.

Table 9: Grade 3–4 Laboratory Abnormalities (≥ 10%) in Cycles 1-12 in Patients Who Received KRd (20/27 mg/m2 Regimen) in ASPIRE

Laboratory Abnormality KRd
(N = 392)
n (%)
Rd
(N = 389)
n (%)
Decreased lymphocytes 182 (46) 119 (31)
Decreased absolute neutrophil count 152 (39) 141 (36)
Decreased phosphorus 122 (31) 106 (27)
Decreased platelets 101 (26) 59 (15)
Decreased total white blood cell count 97 (25) 71 (18)
Decreased hemoglobin 58 (15) 68 (18)
Increased glucose 53 (14) 30 (8)
Decreased potassium 41 (11) 23 (6)
KRd = Kyprolis, lenalidomide, and dexamethasone; Rd = lenalidomide and dexamethasone

Kyprolis In Combination With Dexamethasone

The safety of Kyprolis in combination with dexamethasone was evaluated in two open-label, randomized trials (ENDEAVOR and A.R.R.O.W.).

ENDEAVOR

The safety of Kyprolis 20/56 mg/m2 twice weekly in combination with dexamethasone (Kd) was evaluated in ENDEAVOR [see Clinical Studies]. Patients received treatment for a median duration of 48 weeks in the Kd arm and 27 weeks in the bortezomib/dexamethasone (Vd) arm.

Deaths due to adverse reactions within 30 days of last study treatment occurred in 32/463 (7%) patients in the Kd arm and 21/456 (5%) patients in the Vd arm. The causes of death occurring in patients (%) in the two arms (Kd versus Vd) included cardiac 4 (1%) versus 5 (1%), infections 8 (2%) versus 8 (2%), disease progression 7 (2%) versus 4 (1%), pulmonary 3 (1%) versus 2 (< 1%), renal 1 (< 1%) versus 0 (0%), and other adverse reactions 9 (2%) versus 2 (< 1%).

Serious adverse reactions were reported in 59% of the patients in the Kd arm and 40% of the patients in the Vd arm. In both arms, pneumonia was the most frequently reported serious adverse reaction (8% versus 9%).

Discontinuation due to any adverse reaction occurred in 29% in the Kd arm versus 26% in the Vd arm. The most frequent adverse reaction leading to discontinuation was cardiac failure in the Kd arm (n = 8, 2%) and peripheral neuropathy in the Vd arm (n = 22, 5%). The incidence of cardiac failure events was 11% in the Kd arm versus 3% in the Vd arm.

Adverse reactions in the first 6 months of therapy that occurred at a rate of 10% or greater in the Kd arm are presented in Table 10.

Table 10: Adverse Reactions (≥ 10%) Occurring in Months 1–6 in Patients Who Received Kd (20/56 mg/m2 Regimen) in ENDEAVOR

Adverse Reactions Kd
(N = 463)
n (%)
Vd
(N = 456)
n (%)
Any Grade Grade ≥ 3 Any Grade Grade ≥ 3
Blood and Lymphatic System Disorders
  Anemia 161 (35) 57 (12) 112 (25) 43 (9)
  Thrombocytopeniaa 125 (27) 45 (10) 112 (25) 64 (14)
Gastrointestinal Disorders
  Diarrhea 117 (25) 14 (3) 14 (3) 27 (6)
  Nausea 70 (15) 4 (1) 68 (15) 3 (1)
  Constipation 60 (13) 1 (0) 113 (25) 6 (1)
  Vomiting 45 (10) 5 (1) 33 (7) 3 (1)
General Disorders and Administration Site Conditions
  Fatigue 116 (25) 14 (3) 126 (28) 25 (6)
  Pyrexia 102 (22) 9 (2) 52 (11) 3 (1)
  Asthenia 73 (16) 9 (2) 65 (14) 13 (3)
  Peripheral edema 62 (13) 3 (1) 62 (14) 3 (1)
Infections
  Upper respiratory tract infection 67 (15) 4 (1) 55 (12) 3 (1)
  Bronchitis 54 (12) 5 (1) 25 (6) 2 (0)
Musculoskeletal and Connective Tissue Disorders
  Muscle spasms 70 (15) 1 (0) 23 (5) 3 (1)
  Back pain 64 (14) 8 (2) 61 (13) 10 (2)
Nervous System Disorders
  Headache 67 (15) 4 (1) 39 (9) 2 (0)
  Peripheral neuropathiesb,c 56 (12) 7 (2) 170 (37) 23 (5)
Psychiatric Disorders
  Insomnia 105 (23) 5 (1) 116 (25) 10 (2)
Respiratory, Thoracic and Mediastinal Disorders
  Dyspnead 128 (28) 23 (5) 69 (15) 8 (2)
  Coughe 97 (21) 0 (0) 61 (13) 2 (0)
Vascular Disorders
  Hypertensionf 83 (18) 30 (7) 33 (7) 12 (3)
Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone
a Thrombocytopenia includes platelet count decreased and thrombocytopenia.
b Peripheral neuropathies includes peripheral neuropathy, peripheral sensory neuropathy, and peripheral motor neuropathy.
c See Clinical Studies.
d Dyspnea includes dyspnea and dyspnea exertional.
e Cough includes cough and productive cough.
f Hypertension includes hypertension, hypertensive crisis, and hypertensive emergency.

The event rate of ≥ Grade 2 peripheral neuropathy in the Kd arm was 7% (95% CI: 5, 9) versus 35% (95% CI: 31, 39) in the Vd arm.

Adverse Reactions Occurring At A Frequency Of < 10%

  • Blood and lymphatic system disorders: febrile neutropenia, leukopenia, lymphopenia, neutropenia, thrombotic microangiopathy, thrombotic thrombocytopenic purpura
  • Cardiac disorders: atrial fibrillation, cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, palpitations, tachycardia
  • Ear and labyrinth disorders: tinnitus
  • Eye disorders: cataract, vision blurred
  • Gastrointestinal disorders: abdominal pain, abdominal pain upper, dyspepsia, gastrointestinal hemorrhage, toothache
  • General disorders and administration site conditions: chest pain, chills, influenza like illness, infusion site reactions (including inflammation, pain, and erythema), malaise, pain
  • Hepatobiliary disorders: cholestasis, hepatic failure, hyperbilirubinemia
  • Immune system disorders: drug hypersensitivity
  • Infections: bronchopneumonia, gastroenteritis, influenza, lung infection, nasopharyngitis, pneumonia, rhinitis, sepsis, urinary tract infection, viral infection
  • Metabolism and nutrition disorders: decreased appetite, dehydration, hypercalcemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome
  • Musculoskeletal and connective tissue disorders: muscular weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia
  • Nervous system disorders: cerebrovascular accident, dizziness, hypoesthesia, paresthesia, posterior reversible encephalopathy syndrome
  • Psychiatric disorders: anxiety
  • Renal and urinary disorders: renal failure, renal failure acute, renal impairment
  • Respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, dysphonia, epistaxis, interstitial lung disease, oropharyngeal pain, pneumonitis, pulmonary embolism, pulmonary edema, pulmonary hypertension, wheezing
  • Skin and subcutaneous tissue disorders: erythema, hyperhidrosis, pruritus, rash
  • Vascular disorders: deep vein thrombosis, flushing, hypotension

Table 11 describes Grade 3–4 laboratory abnormalities reported at a rate of ≥ 10% in the Kd arm.

Table 11: Grade 3–4 Laboratory Abnormalities (≥ 10%) in Months 1–6 in Patients Who Received Kd (20/56 mg/m2 Regimen) in ENDEAVOR

Laboratory Abnormality Kd
(N = 463)
n (%)
Vd
(N = 456)
n (%)
Decreased lymphocytes 249 (54) 180 (40)
Increased uric acid 244 (53) 198 (43)
Decreased hemoglobin 79 (17) 68 (15)
Decreased platelets 85 (18) 77 (17)
Decreased phosphorus 74 (16) 61 (13)
Decreased creatinine clearancea 65 (14) 49 (11)
Increased potassium 55 (12) 21 (5)
Kd = Kyprolis and dexamethasone; Vd = bortezomib and dexamethasone
a Calculated using the Cockcroft-Gault formula.

A.R.R.O.W.

The safety of Kyprolis in combination with dexamethasone was evaluated in A.R.R.O.W. [see Clinical Studies]. Patients received treatment for a median duration of 38 weeks in the Kd 20/70 mg/m2 arm once weekly and 29.1 weeks in the Kd 20/27 mg/m2 twice weekly arm. The safety profile for the once weekly Kd 20/70 mg/m2 regimen was similar to the twice weekly Kd 20/27 mg/m2 regimen.

Deaths due to adverse reactions within 30 days of last study treatment occurred in 22/238 (9%) patients in the Kd 20/70 mg/m2 arm and 18/235 (8%) patients in the Kd 20/27 mg/m2 arm. The most frequent fatal adverse reactions occurring in patients (%) in the two arms (once weekly Kd 20/70 mg/m2 versus twice weekly Kd 20/27 mg/m2 ) were sepsis 2 (< 1%) versus 2 (< 1%), septic shock 2 (< 1%) versus 1 (< 1%), and infection 2 (< 1%) versus 0 (0%).

Serious adverse reactions were reported in 43% of the patients in the Kd 20/70 mg/m2 arm and 41% of the patients in the Kd 20/27 mg/m2 arm. In both arms, pneumonia was the most frequently reported serious adverse reaction (8% versus 7%).

Discontinuation due to any adverse reaction occurred in 13% in the Kd 20/70 mg/m2 arm versus 12% in the Kd 20/27 mg/m2 arm. The most frequent adverse reaction leading to discontinuation was acute kidney injury (2% versus 2%). The incidence of cardiac failure events was 3.8% in the once weekly Kd 20/70 mg/m2 arm versus 5.1% in the twice weekly Kd 20/27 mg/m2 arm.

Adverse reactions that occurred at a rate of 10% or greater in either Kd arm are presented in Table 12.

Table 12: Adverse Reactions in Patients Who Received Kd (≥ 10% in either Kd Arm) in A.R.R.O.W.

Adverse Reactions Once weekly Kd 20/70 mg/m2
(N = 238)
n (%)
Twice weekly Kd 20/27 mg/m2
(N = 235)
n (%)
Any Grade Grade ≥ 3 Any Grade Grade ≥ 3
Blood and Lymphatic System Disorders
  Anemiaa 64 (27) 42 (18) 76 (32) 42 (18)
  Thrombocytopeniab 53 (22) 26 (11) 41 (17) 27 (12)
  Neutropeniac 30 (13) 21 (9) 27 (12) 17 (7)
Gastrointestinal Disorders
  Diarrhea 44 (19) 2 (1) 47 (20) 3 (1)
  Nausea 34 (14) 1 (< 1) 26 (11) 2 (1)
General Disorders and Administration Site Conditions
  Pyrexia 55 (23) 2 (1) 38 (16) 4 (2)
  Fatigue 48 (20) 11 (5) 47 (20) 5 (2)
  Asthenia 24 (10) 3 (1) 25 (11) 2 (1)
  Peripheral edema 18 (8) 0 (0) 25 (11) 2 (1)
Infections
  Respiratory tract infectiond 70 (29) 7 (3) 79 (34) 7 (3)
  Pneumonia 28 (12) 24 (10) 20 (9) 16 (7)
  Bronchitis 27 (11) 2 (1) 25 (11) 5 (2)
Musculoskeletal and Connective Tissue Disorders
  Back pain 28 (12) 2 (1) 28 (12) 4 (2)
Nervous System Disorders
  Headache 25 (11) 1 (< 1) 23 (10) 1 (< 1)
Psychiatric Disorders
  Insomnia 35 (15) 2 (1) 47 (20) 0 (0)
Respiratory, Thoracic and Mediastinal Disorders
  Coughe 37 (16) 2 (1) 31 (13) 0 (0)
  Dyspneaf 28 (12) 1 (< 1) 26 (11) 2 (1)
Vascular Disorders
  Hypertensiong 51 (21) 13 (6) 48 (20) 12 (5)
Kd = Kyprolis and dexamethasone
a Anemia includes anemia, hematocrit decreased, and hemoglobin decreased.
b Thrombocytopenia includes platelet count decreased and thrombocytopenia.
c Neutropenia includes neutrophil count decreased and neutropenia.
d Respiratory tract infection includes respiratory tract infection, lower respiratory tract infection, upper respiratory tract infection, and viral upper respiratory tract infection.
e Cough includes cough and productive cough.
f Dyspnea includes dyspnea and dyspnea exertional.
g Hypertension includes hypertension and hypertensive crisis.

Adverse Reactions Occurring at a Frequency of < 10%
  • Blood and lymphatic system disorders: febrile neutropenia, leukopenia, lymphopenia, neutropenia, thrombotic microangiopathy
  • Cardiac disorders: atrial fibrillation, cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia, palpitations, pericardial effusion, tachycardia
  • Ear and labyrinth disorders: tinnitus
  • Eye disorders: cataract, vision blurred
  • Gastrointestinal disorders: abdominal pain, abdominal pain upper, constipation, dyspepsia, toothache, vomiting
  • General disorders and administration site conditions: chest pain, chills, influenza like illness, infusion site reactions (including inflammation, pain, and erythema), malaise, pain
  • Hepatobiliary disorders: cholestasis, hepatic failure, hyperbilirubinemia
  • Infections: clostridium difficile colitis, gastroenteritis, influenza, lung infection, nasopharyngitis, rhinitis, sepsis, septic shock, urinary tract infection, viral infection
  • Metabolism and nutrition disorders: decreased appetite, dehydration, hypercalcemia, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome
  • Musculoskeletal and connective tissue disorders: muscle spasms, muscular weakness, musculoskeletal chest pain, musculoskeletal pain, myalgia
  • Nervous system disorders: cerebrovascular accident, dizziness, paresthesia, peripheral neuropathy
  • Psychiatric disorders: anxiety, delirium
  • Renal and urinary disorders: acute kidney injury, renal failure, renal impairment
  • Respiratory, thoracic and mediastinal disorders: acute respiratory distress syndrome, dysphonia, epistaxis, interstitial lung disease, oropharyngeal pain, pneumonitis, pulmonary hemorrhage, pulmonary embolism, pulmonary hypertension, pulmonary edema, wheezing
  • Skin and subcutaneous tissue disorders: erythema, hyperhidrosis, pruritus, rash
  • Vascular disorders: deep vein thrombosis, flushing, hypotension

Kyprolis In Combination With Intravenous Daratumumab And Dexamethasone

The safety of Kyprolis in combination with intravenous daratumumab and dexamethasone was evaluated in two trials (CANDOR and EQUULEUS).

CANDOR

The safety of Kyprolis 20/56 mg/m2 twice weekly in combination with intravenous daratumumab and dexamethasone (DKd) was evaluated in CANDOR [see Clinical Studies]. Patients received Kyprolis for a median duration of 58 weeks in the DKd arm and 40 weeks in the Kd arm.

Serious adverse reactions were reported in 56% of the patients in the DKd arm and 46% of the patients in the Kd arm. The most frequent serious adverse reactions reported in the DKd arm as compared with the Kd arm were pneumonia (14% versus 9%), pyrexia (4.2% versus 2.0%), influenza (3.9% versus 1.3%), sepsis (3.9% versus 1.3%), anemia (2.3% versus 0.7%), bronchitis (1.9% versus 0%) and diarrhea (1.6% versus 0%). Fatal adverse reactions within 30 days of the last dose of any study treatment occurred in 10% of 308 patients in the DKd arm compared with 5% of 153 patients in the Kd arm. The most frequent fatal adverse reaction (DKd versus Kd) was infection 4.5% versus 2.6%.

Permanent discontinuation due to an adverse reaction in patients who received Kyprolis occurred in 21% of patients in the DKd arm versus 22% in the Kd arm. The most frequent adverse reactions leading to discontinuation of Kyprolis were cardiac failure (1.9%) and fatigue (1.9%) in the DKd arm and cardiac failure (2.0%), hypertension (2.0%) and acute kidney injury (2.0%) in the Kd arm. Interruption of Kyprolis due to adverse reactions occurred in 71% of patients in DKd arm versus 63% in the Kd arm. Dose reduction of Kyprolis due to adverse reactions occurred in 25% of patients in DKd arm versus 20% in the Kd arm.

Infusion-related reactions that occurred following the first Kyprolis dose was 13% in the DKd arm versus 1% in the Kd arm.

Table 13 summarizes the adverse reactions in CANDOR.

Table 13: Adverse Reactions (≥ 15%) in Patients Who Received either DKd or Kd (20/56 mg/m2 Regimen) in CANDOR

Adverse Reactions Twice weekly DKd
(N = 308)
Twice weekly Kd
(N = 153)
All Grades
(%)
Grade 3 or 4
(%)
All Grades
(%)
Grade 3 or 4
(%)
General Disorders and Administration Site Conditions
  Infusion-related reactiona 41 12 28 5
  Fatigueb 32 11 28 8
  Pyrexia 20 1.9 15 0.7
Infections
  Respiratory tract infectionc 40g 7 29 3.3
  Pneumonia 18g 13 12 9
  Bronchitis 17 2.6 12 1.3
Blood and Lymphatic System Disorders
  Thrombocytopeniad 37 25 30 16
  Anemiae 33 17 31 14
Gastrointestinal Disorders
  Diarrhea 32 3.9 14 0.7
  Nausea 18 0 13 0.7
Vascular Disorders
  Hypertension 31 18 28 13
Respiratory, Thoracic and Mediastinal Disorders
  Coughf 21 0 21 0
  Dyspnea 20 3.9 22 2.6
Psychiatric Disorders
  Insomnia 18 3.9 11 2.0
Musculoskeletal and Connective Tissue Disorders
  Back pain 16 1.9 10 1.3
DKd = Kyprolis, daratumumab, and dexamethasone; Kd = Kyprolis and dexamethasone
a The incidence of infusion related reactions is based on a group of symptoms (including hypertension, pyrexia, rash, myalgia, hypotension, blood pressure increased, urticaria, acute kidney injury, bronchospasm, face edema, hypersensitivity, rash, syncope, wheezing, eye pruritus, eyelid edema, renal failure, swelling face) related to infusion reactions which occurred within 1 day after DKd or Kd administration.
b Fatigue includes fatigue and asthenia.
c Respiratory tract infection includes respiratory tract infection, lower respiratory tract infection, upper respiratory tract infection and viral upper respiratory tract infection.
d Thrombocytopenia includes platelet count decreased and thrombocytopenia.
e Anemia includes anemia, hematocrit decreased and hemoglobin decreased.
f Cough includes productive cough and cough.
g Includes fatal adverse reactions.

Adverse Reactions Occurring at a Frequency of < 15%
  • Blood and lymphatic system disorders: febrile neutropenia, thrombotic thrombocytopenic purpura
  • Cardiac disorders: atrial fibrillation, cardiac arrest, cardiac failure, cardiomyopathy, myocardial infarction, myocardial ischemia, tachycardia
  • Eye disorders: cataract
  • Gastrointestinal disorders: abdominal pain, gastrointestinal hemorrhage
  • General disorders and administration site conditions: chest pain, malaise
  • Infections: gastroenteritis, influenza, lung infection, nasopharyngitis, sepsis, septic shock, urinary tract infection, viral infection
  • Investigations: alanine aminotransferase increased, blood creatinine increased, Creactive protein increased, ejection fraction decreased
  • Metabolism and nutrition disorders: dehydration, hyperglycemia, hyperkalemia, hypokalemia, hyponatremia, tumor lysis syndrome
  • Musculoskeletal and connective tissue disorders: pain in extremity
  • Nervous system disorders: cerebrovascular accident, intracranial hemorrhage, posterior reversible encephalopathy syndrome, peripheral neuropathy
  • Psychiatric disorders: anxiety
  • Renal and urinary disorders: acute kidney injury, renal failure, renal impairment
  • Respiratory, thoracic and mediastinal disorders: acute respiratory failure, epistaxis, interstitial lung disease, pneumonitis, pulmonary embolism, pulmonary hypertension, pulmonary edema
  • Skin and subcutaneous tissue disorders: rash
  • Vascular disorders: deep vein thrombosis, hypertensive crisis
EQUULEUS

The safety of Kyprolis 20/70 mg/m2 once weekly in combination with intravenous daratumumab and dexamethasone (DKd) was evaluated in EQUULEUS [see Clinical Studies]. Patients received Kyprolis for a median duration of 66 weeks.

Serious adverse reactions were reported in 48% of patients. The most frequent serious adverse reactions reported were pneumonia (4.7%), upper respiratory tract infection (4.7%), basal cell carcinoma (4.7%), influenza (3.5%), general physical health deterioration (3.5%) and hypercalcemia (3.5%). Fatal adverse reactions within 30 days of the last dose of any study treatment occurred in 3.5% of patients who died of general physical health deterioration, multi-organ failure secondary to pulmonary aspergillosis, and disease progression.

Discontinuation of Kyprolis occurred in 19% of patients. The most frequent adverse reaction leading to discontinuation was asthenia (2%). Interruption of Kyprolis due to adverse reactions occurred in 77% of patients. Dose reduction of Kyprolis due to adverse reactions occurred in 31% of patients in DKd.

Infusion-related reactions that occurred following the first Kyprolis dose was 11%. Pulmonary hypertension adverse reactions were reported in 4.7% of patients in EQUULEUS.

Table 14 summarizes the adverse reactions in EQUULEUS.

Table 14: Adverse Reactions (≥ 15%) in Patients Who Received DKd (20/70 mg/m2 Regimen) in EQUULEUS

Adverse Reactions Once weekly DKd
(N = 85)
All Grades
(%)
Grade 3 or 4
(%)
Blood and Lymphatic System Disorders
  Thrombocytopeniaa 68 32
  Anemiab 52 21
  Neutropeniac 31 21
  Lymphopeniad 29 25
General Disorders and Administration Site Conditions
  Fatiguee 54 18
  Infusion-related reactionf 53 12
  Pyrexia 37 1.2
Infections
  Respiratory tract infectiong 53 3.5
  Bronchitis 19 0
  Nasopharyngitis 18 0
  Influenza 17 3.5
Gastrointestinal Disorders
  Nausea 42 1.2
  Vomiting 40 1.2
  Diarrhea 38 2.4
  Constipation 17 0
Respiratory, Thoracic and Mediastinal Disorders
  Dyspnea 35 3.5
  Coughh 33 0
Vascular Disorders
  Hypertension 33 20
Psychiatric Disorders
  Insomnia 33 4.7
Nervous System Disorders
  Headache 27 1.2
Musculoskeletal and Connective Tissue Disorders
  Back pain 25 0
  Pain in extremity 15 0
DKd = Kyprolis, daratumumab, and dexamethasone; Kd = Kyprolis and dexamethasone
a Thrombocytopenia includes platelet count decreased and thrombocytopenia.
b Anemia includes anemia, hematocrit decreased and hemoglobin decreased.
c Neutropenia includes neutrophil count decreased and neutropenia.
d Lymphopenia includes lymphocyte count decreased and lymphopenia.
e Fatigue includes fatigue and asthenia.
f The incidence of infusion related reactions is based on a group of symptoms (including hypertension, pyrexia, rash, myalgia, hypotension, blood pressure increased, urticaria, acute kidney injury, bronchospasm, face edema, hypersensitivity, rash, syncope, wheezing, eye pruritus, eyelid edema, renal failure, swelling face) related to infusion reactions which occurred within 1 day after DKd administration.

Adverse Reactions Occurring at a Frequency of < 15%
  • Blood and lymphatic system disorders: febrile neutropenia, thrombotic microangiopathy
  • Cardiac disorders: cardiac failure, myocardial ischemia
  • Gastrointestinal disorders: abdominal pain
  • General disorders and administration site conditions: multiple organ dysfunction syndrome
  • Infections: pneumonia, sepsis, septic shock
  • Metabolism and nutrition disorders: dehydration, hypercalcemia
  • Renal and urinary disorders: acute kidney injury, renal failure, renal impairment
  • Respiratory, thoracic and mediastinal disorders: pulmonary embolism, pulmonary hypertension
  • Vascular disorders: hypotension

Kyprolis In Combination With Subcutaneous Daratumumab And Dexamethasone

The safety of Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone was evaluated in PLEIADES [see Clinical Studies].

PLEIADES

The safety of Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone (DKd) was evaluated in a single-arm cohort of PLEIADES. Patients received Kyprolis as a 30-minute IV infusion once weekly for three weeks (Days 1, 8, and 15), followed by a 13-day rest period (Days 16 to 28) and continued until disease progression or unacceptable toxicity (N=66) in combination with daratumumab and hyaluronidase-fihj and dexamethasone. Among these patients, 77% were exposed for 6 months or longer and 27% were exposed for greater than one year.

Serious adverse reactions occurred in 27% of patients who received Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone. Fatal adverse reactionsoccurred in 3% of patients who received Kyprolis in combination with daratumumab and hyaluronidase-fihj and dexamethasone.

Permanent discontinuation of Kyprolis due to an adverse reaction occurred in 6% of patients who received Kyprolis.

Dosage interruptions due to an adverse reaction occurred in 46% of patients who received Kyprolis.

The most common adverse reactions (≥20%) were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea and edema peripheral.

Table 15 summarizes the adverse reactions in patients who received Kyprolis with subcutaneous daratumumab and dexamethasone (DKd) in PLEIADES.

Table 15: Adverse Reactions (≥10%) in Patients Who Received Kyprolis with Subcutaneous Daratumumab and Dexamethasone (DKd) in PLEIADES

Adverse Reaction DKd
(N=66)
All Grades
(%)
Grade ≥3
(%)
Infections and infestations
  Upper respiratory tract infectiona 52 0
  Bronchitisb 12 2#
General disorders and administration site conditions
  Fatiguec 39 2#
  Pyrexia 21 2#
  Edema peripherald 20 0
Psychiatric disorders
  Insomnia 33 6#
Vascular disorders
  Hypertensione 32 21#
Gastrointestinal disorders
  Diarrhea 29 0
  Nausea 21 0
  Vomiting 15 0
Respiratory, thoracic and mediastinal disorders
  Coughf 24 0
  Dyspneag 23 2#
Nervous system disorders
  Headache 23 0
  Peripheral sensory neuropathy 11 0
Musculoskeletal and connective tissue disorders
  Back pain 17 2#
  Musculoskeletal chest pain 11 0
a Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral pharyngitis, and viral upper respiratory tract infection.
b Bronchitis includes bronchitis, and bronchitis viral.
c Fatigue includes asthenia, and fatigue.
d Edema peripheral includes generalized edema, edema peripheral, and peripheral swelling.
e Hypertension includes blood pressure increased, and hypertension.
f Cough includes cough, and productive cough.
g Dyspnea includes dyspnea, and dyspnea exertional.
# Only Grade 3 adverse reactions occurred.

Clinically relevant adverse reactions in <10% of patients who received Kyprolis with subcutaneous daratumumab and dexamethasone include:

  • Gastrointestinal disorders: abdominal pain, constipation, pancreatitis
  • Infection and infestations: pneumonia, influenza, urinary tract infection, herpes zoster, sepsis
  • Metabolism and nutrition disorders: hyperglycemia, decreased appetite, hypocalcemia
  • Musculoskeletal and connective tissue disorders: muscle spasms, arthralgia
  • Nervous system disorders: paresthesia, dizziness, syncope
  • General disorders and administration site conditions: injection site reaction, infusion reactions, chills
  • Skin and subcutaneous tissue disorders: rash, pruritus
  • Cardiac disorders: cardiac failure
  • Vascular disorders: hypotension

Table 16: Select Laboratory Abnormalities (≥30%) Worsening from Baseline in Patients Who Received DKd in PLEIADES

Laboratory Abnormality DKda
All Grades (%) Grades 3-4 (%)
Decreased platelets 88 18
Decreased lymphocytes 83 50
Decreased leukocytes 68 18
Decreased neutrophils 55 15
Decreased hemoglobin 47 6
Decreased corrected calcium 45 2
Increased alanine aminotransferase (ALT) 35 5
a Denominator is based on the safety population treated with DKd (N=66).

Kyprolis In Combination With Isatuximab And Dexamethasone

The safety of Kyprolis in combination with isatuximab and dexamethasone was evaluated in IKEMA, a randomized, open-label clinical trial in patients with previously treated multiple myeloma [see Clinical Studies]. Patients received Kyprolis 20/56 mg/m2 twice weekly in combination with isatuximab and dexamethasone (Isa-Kd) (n=177) or Kyprolis and dexamethasone (Kd) (n=122). Among patients receiving Isa-Kd, the median exposure to Kyprolis was 65 weeks.

Serious adverse reactions occurred in 59% of patients receiving Isa-Kd. The most frequent serious adverse reactions in >5% of patients who received Isa-Kd were pneumonia (25%) and upper respiratory tract infections (9%). Adverse reactions with a fatal outcome during treatment were reported in 3.4% of patients in the Isa-Kd group (those occurring in more than 1% of patients were pneumonia occurring in 1.7% and cardiac failure in 1.1% of patients).

Permanent treatment discontinuation due to an adverse reaction (grades 1-4) occurred in 8% of patients who received Isa-Kd. The most frequent adverse reactions requiring permanent discontinuation in patients who received Isa-Kd were infections (2.8%).

Dosage interruptions due to an adverse reaction occurred in 4% of patients who received Kyprolis in the Isa-Kd group. The most frequent adverse reactions requiring dosage interruption in patients who received Kyprolis in the Isa-Kd group were administration site extravasation (1.1%) and infusion site extravasation (1.1%).

Dose reductions or omissions of Kyprolis due to an adverse reaction in the Isa-Kd group occurred in 67% of patients. Adverse reactions which required dose reductions or omissions in >10% of patients who received Kyprolis in the Isa-Kd group were upper respiratory tract infection (12.4%) and hypertension (11.9%).

The most common adverse reactions (≥20%) were upper respiratory tract infection, infusionrelated reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough and back pain.

Table 17 summarizes the adverse reactions in IKEMA.

Table 17: Adverse Reactions (≥10%) in Patients Who Received Kyprolis with Isatuximab and Dexamethasone (Isa-Kd) in IKEMA

Adverse Reactions Isa-Kd
(N = 177)
Kd
(N = 122)
All Grades
(%)
Grade 3 or 4
(%)
All Grades
(%)
Grade 3 or 4
(%)
Infections
  Upper respiratory tract infectiona 67 9 57 7
  Pneumoniab 36 22 30 18
  Bronchitisc 24 2.3 13 0.8
General Disorders and Administration Site Conditions
  Infusion-related reactiond 46 0.6 3.3 0
  Fatiguee 42 5 32 3.3
Vascular Disorders
  Hypertensionf 37 21 32 20
Gastrointestinal Disorders
  Diarrhea 36 2.8 29 2.5
  Vomiting 15 1.1 9 0.8
Respiratory, Thoracic and Mediastinal Disorders
  Dyspneag 29 5 24 0.8
  Coughh 23 0 15 0
Isa-Kd = Kyprolis, isatuximab, and dexamethasone
a Upper respiratory tract infection includes acute sinusitis, chronic sinusitis, H1N1 influenza, H3N2 influenza, influenza, laryngitis, laryngitis viral, nasal herpes, nasopharyngitis, pharyngitis, pharyngotonsillitis, respiratory syncytial virus infection, rhinitis, sinusitis, sinusitis bacterial, tonsillitis, tracheitis, upper respiratory tract infection, viral rhinitis, respiratory tract infection, respiratory tract infection viral, influenza like illness, parainfluenzae virus infection, respiratory tract infection bacterial, and viral upper respiratory tract infection.
b Pneumonia includes atypical pneumonia, lower respiratory tract infection, lower respiratory tract infection viral, pneumocystis jirovecii pneumonia, pneumonia, pneumonia influenzal, pneumonia legionella, pneumonia pneumococcal, pneumonia respiratory syncytial viral, pneumonia streptococcal, pneumonia viral, pulmonary sepsis, and pulmonary tuberculosis.
c Bronchitis includes bronchitis, bronchitis viral, respiratory syncytial virus bronchitis, bronchitis chronic, and tracheobronchitis.
d Infusion-related reaction includes infusion-related reaction, cytokine release syndrome, and hypersensitivity.
e Fatigue includes fatigue and asthenia.
f Hypertension includes hypertension, blood pressure increased, and hypertensive crisis.
g Dyspnea includes dyspnea and dyspnea exertional.
h Cough includes cough, productive cough, and allergic cough.

Table 18 summarizes the laboratory abnormalities in patients who received Kyprolis with isatuximab and dexamethasone versus Kyprolis with dexamethasone in IKEMA.

Table 18: Hematology Laboratory Abnormalities During the Treatment Period in Patients Who Received Isa-Kd versus Kd in IKEMA

Laboratory Abnormality Isa-Kda
(N=177)
Kd
(N=122)
All Grades
(%)
Grades 3-4
(%)
All Grades
(%)
Grades 3-4
(%)
Hemoglobin decreased 99 22 99 20
Lymphocytes decreased 94 69 95 57
Platelets decreased 94 30 88 24
Neutrophils decreased 55 20 43 8
a Denominator is based on the safety population.

Kyprolis In Patients Who Received Monotherapy

The safety of Kyprolis 20/27 mg/m2 as a 10-minute infusion was evaluated in clinical trials consisting of 598 patients with relapsed and/or refractory myeloma [see Clinical Studies]. Premedication with dexamethasone 4 mg was required before each dose in Cycle 1 and was optional for subsequent cycles. The median age was 64 years (range 32–87), and approximately 57% were male. The patients received a median of 5 (range 1–20) prior regimens. The median number of cycles initiated was 4 (range 1–35).

Deaths due to adverse reactions within 30 days of the last dose of Kyprolis occurred in 30/598 (5%) patients receiving Kyprolis monotherapy. These adverse reactions were related to cardiac disorders in 10 (2%) patients, infections in 8 (1%) patients, renal disorders in 4 (< 1%) patients, and other adverse reactions in 8 (1%) patients.

Serious adverse reactions were reported in 50% of patients in the pooled Kyprolis monotherapy studies (N = 598). The most frequent serious adverse reactions were: pneumonia (8%), acute renal failure (5%), disease progression (4%), pyrexia (3%), hypercalcemia (3%), congestive heart failure (3%), multiple myeloma (3%), anemia (2%), and dyspnea (2%).

In FOCUS, a randomized trial comparing Kyprolis as a single agent versus corticosteroids with optional oral cyclophosphamide for patients with relapsed and refractory multiple myeloma, mortality was higher in the patients treated with Kyprolis in comparison to the control arm in the subgroup of 48 patients ≥ 75 years of age. The most common cause of discontinuation due to an adverse reaction was acute renal failure (2%).

Safety of Kyprolis monotherapy dosed at 20/56 mg/m2 by 30-minute infusion was evaluated in a multicenter, open-label study in patients with relapsed and/or refractory multiple myeloma [see Clinical Studies]. The patients received a median of 4 (range 1–10) prior regimens.

Adverse reactions occurring with Kyprolis monotherapy are presented in Table 19.

Table 19: Adverse Reactions (≥ 20%) with Kyprolis Monotherapy

Adverse Reactions 20/56 mg/m2
by 30-minute infusion
(N = 24)
20/27 mg/m2
by 2- to 10-minute infusion
(N = 598)
All Grades
n (%)
Grades 3-5
n (%)
All Grades
n (%)
Grades 3-5
n (%)
Fatigue 14 (58) 2 (8) 238 (40) 25 (4)
Dyspneaa 14 (58) 2 (8) 202 (34) 21 (4)
Pyrexia 14 (58) 0 177 (30) 11 (2)
Thrombocytopenia 13 (54) 13 (54) 220 (37) 152 (25)
Nausea 13 (54) 0 211 (35) 7 (1)
Anemia 10 (42) 7 (29) 291 (49) 141 (24)
Hypertensionb 10 (42) 3 (13) 90 (15) 22 (4)
Chills 9 (38) 0 73 (12) 1 (< 1)
Headache 8 (33) 0 141 (24) 7 (1)
Coughc 8 (33) 0 134 (22) 2 (< 1)
Vomiting 8 (33) 0 104 (17) 4 (1)
Lymphopenia 8 (33) 8 (33) 85 (14) 73 (12)
Insomnia 7 (29) 0 75 (13) 0
Dizziness 7 (29) 0 64 (11) 5 (1)
Diarrhea 6 (25) 1 (4) 160 (27) 8 (1)
Blood creatinine increased 6 (25) 1 (4) 103 (17) 15 (3)
Peripheral edema 5 (21) 0 118 (20) 1 (< 1)
Back pain 5 (21) 1 (4) 115 (19) 19 (3)
Upper respiratory tract infection 5 (21) 1 (4) 112 (19) 15 (3)
Decreased appetite 5 (21) 0 89 (15) 2 (< 1)
Muscle spasms 5 (21) 0 62 (10) 2 (< 1)
Chest pain 5 (21) 0 20 (3) 1 (< 1)
a Dyspnea includes dyspnea and dyspnea exertional.
b Hypertension includes hypertension, hypertensive crisis, and hypertensive emergency.
c Cough includes cough and productive cough.

Adverse Reactions Occurring at a Frequency of < 20%
  • Blood and lymphatic system disorders: febrile neutropenia, leukopenia, neutropenia
  • Cardiac disorders: cardiac arrest, cardiac failure, cardiac failure congestive, myocardial infarction, myocardial ischemia
  • Ear and labyrinth disorders: tinnitus
  • Eye disorders: cataract, blurred vision
  • Gastrointestinal disorders: abdominal pain, abdominal pain upper, constipation, dyspepsia, gastrointestinal hemorrhage, toothache
  • General disorders and administration site conditions: asthenia, infusion site reaction, multi-organ failure, pain
  • Hepatobiliary disorders: hepatic failure
  • Infections: bronchitis, bronchopneumonia, influenza, lung infection, pneumonia, nasopharyngitis, respiratory tract infection, rhinitis, sepsis, urinary tract infection
  • Metabolism and nutrition disorders: hypercalcemia, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, tumor lysis syndrome
  • Musculoskeletal and connective tissue disorders: arthralgia, musculoskeletal pain, musculoskeletal chest pain, myalgia, pain in extremity
  • Nervous system disorders: hypoesthesia, intracranial hemorrhage, paresthesia, peripheral motor neuropathy, peripheral neuropathy, peripheral sensory neuropathy
  • Psychiatric disorders: anxiety
  • Renal and urinary disorders: acute renal failure, renal failure, renal impairment
  • Respiratory, thoracic and mediastinal disorders: dysphonia, epistaxis, oropharyngeal pain, pulmonary edema, pulmonary hemorrhage
  • Skin and subcutaneous tissue disorders: erythema, hyperhidrosis, pruritus, rash
  • Vascular disorders: embolic and thrombotic events, venous (including deep vein thrombosis and pulmonary embolism), hemorrhage, hypotension

Grade 3 and higher adverse reactions occurring at an incidence of > 1% include febrile neutropenia, cardiac arrest, cardiac failure congestive, pain, sepsis, urinary tract infection, hyperglycemia, hyperkalemia, hyperuricemia, hypoalbuminemia, hypocalcemia, hyponatremia, hypophosphatemia, renal failure, renal failure acute, renal impairment, pulmonary edema, and hypotension.

Table 20 describes Grade 3–4 laboratory abnormalities reported at a rate of > 10% for patients who received Kyprolis monotherapy.

Table 20: Grade 3–4 Laboratory Abnormalities (> 10%) with Kyprolis Monotherapy

Laboratory Abnormality Kyprolis
20/56 mg/m2
(N = 24)
Kyprolis
20/27 mg/m2
(N = 598)
Decreased lymphocytes 15 (63) 151 (25)
Decreased platelets 11 (46) 184 (31)
Decreased hemoglobin 7 (29) 132 (22)
Decreased total white blood cell count 3 (13) 71 (12)
Decreased sodium 2 (8) 69 (12)
Decreased absolute neutrophil count 2 (8) 67 (11)

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of Kyprolis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: hemolytic uremic syndrome (HUS), hepatitis B virus reactivation, gastrointestinal perforation, pericarditis, and cytomegalovirus infection, including chorioretinitis, pneumonitis, enterocolitis, viremia, intestinal obstruction, and acute pancreatitis.

DRUG INTERACTIONS

No Information Provided

Read the entire FDA prescribing information for Kyprolis (Carfilzomib)

© Kyprolis Patient Information is supplied by Cerner Multum, Inc. and Kyprolis Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors